Hairy cell leukemia: New therapeutic strategies?;Leucemie a tricholeucocytes: Nouveaux choix therapeutiques?

Hematologie

Volumn 2, Issue 3, 1996, Pages 251-261

  Castaigne, Sylvie ^a   Catovsky, Daniel ^b   Delannoy, André ^c   Michaux, Jean Louis ^c   Troussard, Xavier ^d  

^a CENTRE HOSPITALIER DE VERSAILLES   (France)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; CLADRIBINE; PENTOSTATIN;

HAIRY CELL LEUKEMIA; INTRAVENOUS DRUG ADMINISTRATION; SHORT SURVEY;

EID: 0344518246     PISSN: 12647527     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (31)

1. Bastie JN, d'Agay MF, Flandrin G, Daniel MT, Dabout D, Glaisner S, Degos L, Castaigne S. Hairy cell leukemia (HCL): a phase II prospective study about 28 patients treated with 2-chlorodeoxyadenosine (2 CdA). Br J Haematol 1995; 87 (Suppl. 1): 351a.
2. Lauria F, Raspadori D, Foa R, Zinzani P, Buzzi M, Gugliotta L. Reduced hematologic response to alpha-interferon therapy in patients with hairy cell leukemia showing a peculiar immunologic phenotype. Cancer 1990; 65 : 2233-6.
3. Sainati L, Matutes E, Mulligan S, de Oliveira MP, Rani S, Lampert IA, Catovsky D. A variant form of hairy cell leukemia resistant to α-interferon: clinical and phenotypic characteristics of 17 patients. Blood 1990; 76: 157-62.
4. Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD. 2-chlarodexyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk Lymph 1991; Suppl.: 133-8.
5. Juliusson G, Heldal D, Hippe E, Hedenus M, Malm C, Wallman K, Stolt C-M, Evensen SA, Albertioni F, Tjønnfjord G, Lenkei R, Liliemark J. Subcutaneous injections of 2-chlorodeoxyodenosine for symptomatic hairy cell leukemia. J Clin Oncol 1995; 13: 989-95.
6. Liliemark J, Albertioni F, Hassan M, Juliusson G. On the bioavailability of oral and subcutaneous 2-chloro-2′-deoxyodenosine in humans: alternative routes of administration. J Clin Oncol 1992; 10: 1514-8.
7. Tallman MS, Hakimian D. Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorder Blood 1995; 86: 2463-74.
8. Hounieu H, Chittal SM, al Saati T, de Mascarel A, Sabattini E, Pileri S, Ralfkiner E, Le Tourneau A, Selves J, Voigt JJ, Laurent G, Diebold J, Delsol G. Hairy cell leukemia. Diagnosis of bone marrow involvement in porrafin-embedded sections with monoclonal antibody DBA 44. Am J Clin Pathol 1992; 98: 26.
9. Ellison DJ, Sharpe RW, Robbins BA, Spinosa JC, Leopard JD, Saven A, Piro LD. Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 1994; 84: 4310-5.
10. Tallman M, Hakimian D, Zanzig C, Rademaker A, Wollins E, Pzeterson L. Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the northwestern university experience. Blood 1995; 86: 608a.
11. Filleul B, Delannoy A, Ferrant A, Zenebergh A, Van Daele S, Bosly A, Doyen C, Mineur P, Glorieux P, Driesschaert P, Sokal G, Martiat P, Michaux JL. A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission. Leukemia 1994; 7: 1153-6.
12. Wheaton S, Tallman MS, Hakimian D, Peterson L. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood 1994; 87: 1556-60.
13. Catovsky D, Matutes E, Talavera JG, O'Connor NTJ, Johnson SAN, Emmett E, Corbett L, Swansbury J. Long term results with 2′ deoxycoformycin in hairy cell leukemia. Leuk Lymph 1994; 14 (suppl. 1): 109-13.
14. Rai KR, Davey F, Peterson B, Schiffer C, Silver RT, Ozer H, Golomb H, Bloomfield CD. Recombinont alpha 2-b interferon in therapy of previously untreated hairy cell leukemia: long term followup results of study by Cancer and Leukemia Group B. Leukemia 1995; 9: 1116-20.
15. +. lymphocytes counts in patients with hairy cell leukemia. Blood 1994; 83: 2906-11.
16. Urbo WJ, Baseler WC, Steis RG, Clark JW, Smith JWH, Coggin DL, Long DL Deoxycoformycin induced immunosupression in patients with hairy cell leukemia. Blood 1989 ; 73: 38-46.
17. Juliusson G, Liliemark J. Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2′deoxyadenosine (CdA) : relation to opportunistic infections. Blood 1992; 79: 888-94.
18. Juliusson G, Lenkei R, Liliemark J. Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine. Blood 1994; 83: 3672-81.
19. Piro LD, Saven A. The Scripps clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia. Leuk Lymph 1994 ; 14 (suppl. 1): 121-5.
20. Grever M, Kopecky K, Foucar MK, Head D, Bennett JM, Hutchison RE, Corbett WEN, Cassileth PA, Habermann T, Golomb H, Rai K, Eisenhauer E, Appelbaum F, Cheson BD. Randomized comparison of pentostatin versus interferon alpha-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 1995; 13: 974-82.
21. Troussard X, Flandrin G. Hairy cell leukemia. An update on a cohort of 93 patients treated in a single institution. Effects of interferon in patients relapsing after splenectomy and in patients with or without maintenance treatment. Leuk Lymph 1994; 14 (suppl. 1): 99-105.
22. Smith JW, Longo DL, Urba WJ, Clark JW, Watson T, Beveridge J, Conlon KC, Sznol M, Creekmore SP, Alvord GA, Lawrence JB, Steis RG. Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interferon alpha-2a. Blood 1991; 78: 1664-71.
23. Mercieca J, Matutes E, Emmett E, Coles H. Catovsky D. 2-chlorodeoxyadenosine in the treatment of hairy cell leukaemia: differences in response in patients with and without abdominal lymphadenopathy. Br J Haematol 1996 (in press).
24. Kraut EH, Grever MR, Bouroncle BA. Long-term follow-up of patients with hairy cell leukemia after treatment with 2′-deoxycoformycin. Blood 1994; 84: 4061-3.
25. Hoffman M, Janson D, Aggarwal A, Rai KR. Long term results after treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Blood 1995; 86: 351a.
26. Gobmb HM, Fefer A, Golde H, Ozer H, Portlock CS, Silber J, Rapeport J, Ratain MJ, Thompson J, Thompson J, Spiegel R, Tensen L, Burke JS, Vardiman JW. Survival experience of 195 patients with hairy cell leukemia treated in a multi-institutionnal study with interferon alpha-2b. Leuk Lymph 1991; 4: 99-102.
27. Seymour JF, Estey EH, Keating MJ, Kurzrock R. Response to interferon α in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine. Leukemia 1995 ; 9: 929-32.
28. Pawson R, A'Hern R, Catovsky D. Second malignancy in hairy cell leukaemia: no evidence of increased incidence after treatment with interferon alpha. Leuk lymph 1990 (in press).
29. Jacobs RH, Vokes EE, Golomb HM. Second malignancies in hairy cell leukemia. Cancer 1985; 56: 1462-7.
30. Kampmeier P, Spielberger R, Dickstein J, Mick R, Golomb H, Vardiman JW. Increased incidence of second neoplasms in patients treated with interferon α 2b for hairy cell leukemia ; a clinicopathologic assessment. Blood 1994 ; 83: 2932-8.
31. Troussord X, Henry-Amar M, Flandrin G. Second cancer risk after interferon therapy? Blood 1994; 84: 3242-4.